Netflix's "Unnatural Selection" Ducks the Big Questions About Gene Editing
By Jonathan R. Latham,
Salon
| 11. 10. 2019
The opening scene of "Unnatural Selection," a four-part docuseries released recently from Netflix, depicts scientist Jennifer Doudna showing off a tiny sample of a colorless liquid. It contains, she says, an enzyme that allows her to add or remove any piece of DNA from any living organisms. This scene launches an exploration of the people who are taking up — and talking up — that opportunity, which Doudna did much to bring about. In this scene though, as in the remainder of the series, there is scant pushback on the hyperbolic narratives tracked over the four episodes. But, having built up the potential of gene editing, "Unnatural Selection" fails to explore the qualifications and correctives that call into question the whole project of gene editing. One wonders, in fact, if the filmmakers were even aware of the larger existential questions it raises.
The protagonists of the series span an extraordinarily wide spectrum. Spark Therapeutics claims to have invented a gene therapy cure for a special kind of inherited blindness. The biotech company has chosen its smooth-talking and sharply dressed company...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...